Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | AGER | Q15109 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | CFTR | P13569 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL69990 | 1.00 | L3MBTL1 (0.62) | L3MBTL1TDP1MAP2K1KDM4EALDH1A1 | |
| SCHEMBL2800466 | 0.89 | L3MBTL1 (0.54) | L3MBTL1TDP1MAP2K1KDM4EALDH1A1 | |
| SCHEMBL30503698 | 0.89 | KDM4E (0.67) | L3MBTL1TDP1MAP2K1KDM4EALDH1A1 | |
| SCHEMBL29559479 | 0.89 | KDM4E (0.67) | L3MBTL1TDP1MAP2K1KDM4EALDH1A1 | |
| SCHEMBL9632137 | 0.89 | L3MBTL1 (0.58) | L3MBTL1TDP1MAP2K1KDM4EALDH1A1 | |
| SCHEMBL519094 | 0.89 | KDM4E (0.67) | L3MBTL1TDP1MAP2K1KDM4EALDH1A1 | |
| SCHEMBL519095 | 0.89 | KDM4E (0.67) | L3MBTL1TDP1MAP2K1KDM4EALDH1A1 | |
| SCHEMBL13485365 | 0.87 | L3MBTL1 (0.57) | L3MBTL1TDP1MAP2K1KDM4EALDH1A1 | |
| SCHEMBL2372518 | 0.87 | L3MBTL1 (0.57) | L3MBTL1TDP1MAP2K1KDM4EALDH1A1 | |
| SCHEMBL30452153 | 0.87 | L3MBTL1 (0.57) | L3MBTL1TDP1MAP2K1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117756780-A | Efficient and clean treatment method for synthesizing imazamox | 江苏扬农化工股份有限公司 | 2024-03-26 | — | — | CN | claimed |
| CN-115322350-A | Degradable bio-based polyester and preparation method and application thereof | 苏州瀚海新材料有限公司 | 2022-11-11 | — | — | CN | claimed |
| CN-114478477-A | Synthesis process of imazamox | 江苏中旗科技股份有限公司 | 2022-05-13 | — | — | CN | claimed |
| EP-3983416-B1 | CGRP ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-09-03 | — | — | EP | disclosed |
| CN-120271500-A | Novel compound containing pyridine-2, 3-dicarboxylic acid dimethyl ester group and preparation method thereof | 山东龙华生物股份有限公司 | 2025-07-08 | — | — | CN | disclosed |
| CN-120271500-A | Novel compound containing pyridine-2, 3-dicarboxylic acid dimethyl ester group and preparation method thereof | 山东龙华生物股份有限公司 | 2025-07-08 | — | — | CN | disclosed |
| US-12344621-B2 | CGRP antagonist compounds | NXERA PHARMA UK LIMITED (GB) | 2025-07-01 | — | — | US | disclosed |
| CN-115703776-B | Plasmin inhibitor, preparation method and application thereof | 赛诺哈勃药业（成都）有限公司 | 2025-06-17 | — | — | CN | disclosed |
| CN-119954801-A | TAU protein targeting compounds and related methods of use | 阿尔维纳斯运营股份有限公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-119504703-A | Methoxydim plant method for purifying smoke | 湖北泰盛化工有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-114867727-B | TAU protein targeting compounds and related methods of use | 阿尔维纳斯运营股份有限公司 | 2025-02-21 | — | — | CN | disclosed |
| CN-114728977-A | Pyrimidone derivatives containing two fused bicyclic rings | 巴斯夫欧洲公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2022143911-A1 | PLASMIN INHIBITOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 赛诺哈勃药业（成都）有限公司 | 2022-07-07 | — | — | WO | disclosed |
| EP-3999182-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| CN-114478477-A | Synthesis process of imazamox | 江苏中旗科技股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-114478477-A | Synthesis process of imazamox | 江苏中旗科技股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-3983417-A1 | CGRP ANTAGONIST COMPOUNDS | Heptares Therapeutics Limited (GB) | 2022-04-20 | — | — | EP | disclosed |
| EP-3983416-A1 | CGRP ANTAGONIST COMPOUNDS | Heptares Therapeutics Limited (GB) | 2022-04-20 | — | — | EP | disclosed |
| CN-114245798-A | CGRP antagonist compounds | 赫普泰雅治疗有限公司 | 2022-03-25 | — | — | CN | disclosed |
| CN-114245797-A | CGRP antagonist compounds | 赫普泰雅治疗有限公司 | 2022-03-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12344621-B2 | CGRP antagonist compounds | CALCRL, CALCR, CALCA | L3MBTL1 2146/4885TDP1 1158/4885MAP2K1 4422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.